392 related articles for article (PubMed ID: 30483908)
1. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
Saif MW
Clin Colorectal Cancer; 2005 Jul; 5(2):89-100. PubMed ID: 16098249
[TBL] [Abstract][Full Text] [Related]
3. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
4. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
Benson AB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
6. Practical considerations in the use of oral fluoropyrimidines.
Hoff PM
Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review.
Saif MW; Hashmi S; Zelterman D; Almhanna K; Kim R
Int J Colorectal Dis; 2008 Feb; 23(2):139-45. PubMed ID: 17909820
[TBL] [Abstract][Full Text] [Related]
9. The evolution of fluoropyrimidine therapy: from intravenous to oral.
Hoff PM; Cassidy J; Schmoll HJ
Oncologist; 2001; 6 Suppl 4():3-11. PubMed ID: 11585968
[TBL] [Abstract][Full Text] [Related]
10. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
Twelves C; Gollins S; Grieve R; Samuel L
Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
12. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.
Hansen RM; Ryan L; Anderson T; Krzywda B; Quebbeman E; Benson A; Haller DG; Tormey DC
J Natl Cancer Inst; 1996 May; 88(10):668-74. PubMed ID: 8627643
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine: effective oral fluoropyrimidine chemotherapy.
McKendrick J; Coutsouvelis J
Expert Opin Pharmacother; 2005 Jun; 6(7):1231-9. PubMed ID: 15957975
[TBL] [Abstract][Full Text] [Related]
14. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
15. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
[TBL] [Abstract][Full Text] [Related]
16. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
17. Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis.
Zhang L; Xing X; Meng F; Wang Y; Zhong D
J Gastroenterol Hepatol; 2018 Jan; 33(1):209-225. PubMed ID: 28608993
[TBL] [Abstract][Full Text] [Related]
18. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe?
El-Khoueiry AB; Lenz HJ
Cancer Invest; 2006 Feb; 24(1):50-5. PubMed ID: 16466993
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Ku GY; Haaland BA; de Lima Lopes G
Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
[TBL] [Abstract][Full Text] [Related]
20. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]